Binkley, N. http://orcid.org/0000-0002-9905-461X
Orwoll, E.
Chapurlat, R. http://orcid.org/0000-0001-8214-6385
Langdahl, B. L. http://orcid.org/0000-0002-8712-7199
Scott, B. B. http://orcid.org/0000-0003-0963-044X
Giezek, H.
Santora, A. C. http://orcid.org/0000-0001-6040-7935
Funding for this research was provided by:
Merck Sharp and Dohme
Article History
Received: 5 June 2020
Accepted: 13 October 2020
First Online: 17 November 2020
Compliance with ethical standards
:
: BBS, HG, and ACS are, or were at the time of study conduct, employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and may own stock and/or stock options in the company. NB has received research support from Radius and is a consultant for Amgen. RC has been a consultant and/or has given talks for AbbVie, Amgen, Bristol-Myers Squibb, Chugai, Janssen-Cilag, Lilly, MSD, Pfizer, Radius, Sandoz, and UCB. BLL has received research grants (institution) from Amgen and Novo Nordisk and has been involved in advisory boards and lecturing for Amgen, Eli Lilly, MSD, and UCB. EO has received research support from Lilly and Mereo and provides consulting for Bayer and Amgen. ACS is currently a consultant and Chief Medical Officer of Entera Bio Ltd.
: The study was conducted in accordance with the principles of Good Clinical Practice and was approved by the appropriate institutional review boards and regulatory agencies.
: All participants provided written informed consent before any study procedure was initiated.
: Not applicable.
: Not applicable.